
    
      This is a three-period study, with an open-label, single-arm active treatment in Period 1
      followed by a randomized-withdrawal, double-blinded, placebo-controlled design in Period 2,
      and an open label, long-term safety follow-up in Period 3. The total study duration is
      approximately 3 - 4 years.

      During Period 2, subjects will be randomized to MAS825 or matching placebo in a 1:1 ratio.
    
  